^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Cervical Cancer |
| Drug: | Aibining (geptanolimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A multicenter, open-label, single-arm, phase II trial to evaluate the efficacy and safety of geptanolimab (GB226) in the treatment of patients (pts) with programmed cell death ligand 1 (PD-L1)–positive recurrent or metastatic cervical cancer, for whom prior platinum-containing chemotherapy has failed.
Published date:
05/25/2023
Excerpt:
In part 2, PD-L1 positive (CPS≥1) pts with recurrent or metastatic cervical cancer who had received one or more lines of platinum-containing chemotherapy were enrolled and treated with GB226….GB226 demonstrated durable antitumor activity and manageable safety profile in pts with recurrent or metastatic cervical cancer.
DOI:
10.1200/JCO.2023.41.16_suppl.5535
Trial ID:
